Group 1 - The core viewpoint of the news is that Kexing Pharmaceutical has shown significant stock performance this year, with a year-to-date increase of 104.26% despite recent declines in the short term [2] - As of August 22, Kexing Pharmaceutical's stock price reached 44.49 yuan per share, with a market capitalization of 8.954 billion yuan [1] - The company has experienced a net inflow of main funds amounting to 3.3589 million yuan, with large orders accounting for 23.33% of total buying [1] Group 2 - Kexing Pharmaceutical has appeared on the stock market's "Dragon and Tiger List" six times this year, with the most recent appearance on July 3 [3] - The company reported a revenue of 354 million yuan for the first quarter of 2025, reflecting a year-on-year decrease of 1.97% [3] - As of March 31, 2025, the number of shareholders decreased by 10.15% to 8,054, while the average circulating shares per person increased by 11.30% to 24,787 shares [3]

科兴生物制药股份有限公司 2025 年第一次临时股东大会会议资料 证券代码：688136 证券简称：科兴制药 科兴生物制药股份有限公司 2025 年第一次临时股东大会 会议资料 $$\Xi{\bf{o}}{\bf{\mathrm{-}}}\Xi{\bf{H}}\Xi/\backslash\Xi$$ 科兴生物制药股份有限公司 2025 年第一次临时股东大会会议资料 科兴生物制药股份有限公司 2025 年第一次临时股东大会会议资料目录 | 2025 | | 年第一次临时股东大会会议须知 1 | | --- | --- | --- | | 2025 | | 年第一次临时股东大会会议议程 3 | | 2025 | | 年第一次临时股东大会会议议案 5 | | | 议案一 | 关于取消监事会、变更注册资本暨修订《公司章程》的议案 5 | | | 议案二 | 关于修订公司治理制度的议案 6 | | | 议案三 | 关于公司拟发行科技创新债券的议案 7 | | | 议案四 | 关于董事会换届选举暨提名第三届董事会非独立董事的议案 8 | | | 议案五 | 关于董事会换届选举暨提名第三届董事会独立董事的议案 9 | 科兴生 ...

Core Viewpoint - The company, Kexing Pharmaceutical, is actively pursuing funding to support its new drug development and international commercialization efforts, indicating a strategic focus on growth in the biopharmaceutical sector [1] Company Overview - Kexing Pharmaceutical's latest stock price is 44.63 yuan, reflecting a 0.56% increase from the previous trading day [1] - The stock reached a high of 44.91 yuan and a low of 43.26 yuan during the trading session, with a total transaction volume of 314 million yuan and a turnover rate of 3.53% [1] - The company specializes in the research, development, production, and sales of recombinant protein drugs and microbiome preparations, with key products including recombinant human erythropoietin, recombinant human interferon α1b, and Clostridium butyricum dual live bacteria [1] Financial Activities - The company plans to apply for the registration of technology innovation bonds not exceeding 800 million yuan to support new drug research and overseas commercialization [1] - The board has approved a resolution to provide interest-free loans of up to 20 million yuan to its wholly-owned subsidiary, specifically for the upgrade of the research and development center [1] Capital Flow - On the day of reporting, the net outflow of main funds was 6.722 million yuan, with a cumulative net outflow of 78.8172 million yuan over the past five trading days [1]

Core Points - Company announced the convening of the 28th meeting of the second board and the 24th meeting of the second supervisory board on August 14, 2025 [2] - The board approved a proposal to provide interest-free loans to its wholly-owned subsidiary, Shenzhen Kexing Pharmaceutical, using part of the raised funds [2] - The total amount of the interest-free loan will not exceed 20 million yuan, aimed at advancing the construction and implementation of the fundraising project [2] - The loan term is set for three years from the actual borrowing date, with provisions for renewal or early repayment subject to the general manager's approval [2]

Group 1 - The core point of the article is that Kexing Pharmaceutical announced the approval of several proposals, including the use of part of the raised funds to provide interest-free loans to its wholly-owned subsidiary for the implementation of fundraising projects [2] Group 2 - The announcement was made during the 28th meeting of the second board of directors [2] - The decision reflects the company's strategy to support its subsidiary in executing investment projects [2] - The funding mechanism involves utilizing raised capital, indicating a focus on internal resource allocation for growth [2]

Group 1 - The core point of the article is that Kexing Pharmaceutical announced the approval of several proposals, including the use of part of the raised funds to provide interest-free loans to its wholly-owned subsidiary for the implementation of fundraising projects [2] Group 2 - The second meeting of the second supervisory board of Kexing Pharmaceutical took place on August 15, where multiple proposals were reviewed and approved [2] - The specific proposal involves using part of the raised funds to support the subsidiary's projects, indicating a strategic move to enhance operational capabilities [2]

Group 1 - The core point of the article is that Kexing Pharmaceutical announced the convening of its 28th board meeting on August 14, 2025, to discuss various proposals, including the establishment of certain systems [1] - For the year 2024, Kexing Pharmaceutical's revenue composition is as follows: 99.59% from pharmaceutical manufacturing, 0.25% from other businesses, and 0.16% from other sources [1] - As of the report date, Kexing Pharmaceutical has a market capitalization of 9 billion yuan [1] Group 2 - Huakang Co., Ltd. is facing scrutiny over an 11 billion yuan acquisition, as the major client of the acquisition target has been in a debt crisis for two years, raising questions about its ability to contribute significant revenue [1]

Meeting Overview - The second meeting of the second supervisory board of the company was held on August 14, 2025, with all three supervisors present [1]. Resolutions Passed Use of Raised Funds - The supervisory board approved the proposal to provide interest-free loans from raised funds to the wholly-owned subsidiary Shenzhen Kexing Pharmaceutical for project implementation, aligning with the fundraising plan and benefiting project execution [1]. Foreign Exchange Derivative Transactions - The board approved the proposal for the company and its subsidiaries to engage in foreign exchange derivative transactions, with a limit of 75 million RMB or equivalent foreign currency, to mitigate foreign exchange risk and enhance financial stability [2]. Related Party Transaction Agreement - The board approved the signing of a supplementary agreement for related party transactions, confirming compliance with regulations and ensuring no adverse effects on the company's financial status or shareholder interests [2]. Issuance of Technology Innovation Bonds - The board approved the proposal for the company to issue technology innovation bonds, affirming that it aligns with the overall interests of the company and shareholders [3].

是否需要提交股东大会审议：否 对上市公司的影响：科兴生物制药股份有限公司（以下简称"公司"）全 资子公司与关联方签署关联交易补充协议是为了满足子公司日常业务发展需要， 为正常的持续性合作。公司关联交易符合相关法律、法规的规定，关联交易的定 价主要遵循市场价格和公开、公平、公正及合理的原则，没有损害公司及股东的 利益，不会对公司的独立性产生影响，也不会对关联方形成较大的依赖。 一、日常关联交易基本情况 （一）关联交易概述 公司全资子公司深圳科兴药业有限公司（以下简称"深圳科兴"）向正中产 业控股集团有限公司（以下简称"正中产控"）租赁房产，作为深圳科兴日常经 营使用，双方于 2018 年 8 月 30 日签署《房屋租赁合同》（以下简称"原租赁协 议"），租赁期限自 2018 年 9 月 1 日至 2028 年 12 月 31 日。 证券代码：688136 证券简称：科兴制药 公告编号：2025-063 科兴生物制药股份有限公司 关于签署关联交易协议补充协议的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： ...

为有效防范汇率大幅波动对公司经营业绩造成不利影响，提高外汇资金 使用效率，科兴生物制药股份有限公司（以下简称"公司"）及合并报表范围内 子公司拟使用自有资金开展总金额不超过7,500万元人民币或等值外币的外汇衍 生品交易，包括但不限于远期结售汇、人民币和其他外汇的掉期、外汇期权、利 率互换、利率掉期、利率期权等。公司及控股子公司开展外汇衍生品交易业务的 交易对手为具有外汇衍生品交易业务经营资格、经营稳健且资信良好的金融机构。 上述交易额度的使用期限自公司董事会审议通过之日起至2025年12月31日，有效 期内可以滚动使用，但在授权使用有效期内任一时点的金额不应超过审议额度。 公司于2025年8月14日召开第二届董事会第二十八次会议，审议通过了 《关于开展2025年度外汇衍生品交易业务的议案》，该议案无需提交公司股东会 审议。本项业务不构成关联交易。 特别风险提示：公司开展外汇衍生品交易业务遵循合法、谨慎、安全和 有效的原则，不进行单纯以盈利为目的的投机和套利交易，但外汇衍生品交易业 务仍存在包括但不限于市场风险、流动性风险、内部控制风险和履约风险等，敬 请广大投资者注意投资风险。 一、交易情况概述 证券代码： ...